Bailard Inc. raised its holdings in Danaher Co. (NYSE:DHR) by 41.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,842 shares of the conglomerate’s stock after acquiring an additional 23,795 shares during the quarter. Bailard Inc.’s holdings in Danaher were worth $7,504,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also made changes to their positions in the business. Point72 Asset Management L.P. grew its position in shares of Danaher by 276.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock worth $225,332,000 after buying an additional 1,929,751 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Danaher by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP grew its position in shares of Danaher by 52.9% during the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after buying an additional 1,425,000 shares in the last quarter. Koch Industries Inc. grew its position in shares of Danaher by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Danaher by 86.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock worth $256,136,000 after buying an additional 1,393,165 shares in the last quarter. 77.05% of the stock is currently owned by institutional investors.
Danaher Co. (DHR) traded up $0.55 during trading on Wednesday, reaching $97.40. The company’s stock had a trading volume of 82,072 shares, compared to its average volume of 2,721,179. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Co. has a 52 week low of $78.97 and a 52 week high of $104.82. The stock has a market capitalization of $67,946.36, a PE ratio of 27.58, a PEG ratio of 2.05 and a beta of 1.04.
Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period last year, the business posted $1.05 earnings per share. The firm’s revenue was up 10.9% compared to the same quarter last year. equities research analysts predict that Danaher Co. will post 4.37 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Thursday, March 29th will be paid a $0.16 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a yield of 0.66%. Danaher’s dividend payout ratio (DPR) is 15.86%.
A number of research firms have recently issued reports on DHR. Morgan Stanley increased their price target on Danaher from $103.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. Credit Suisse Group increased their price target on Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Evercore ISI initiated coverage on Danaher in a research report on Wednesday, January 3rd. They set an “outperform” rating on the stock. Argus upped their price objective on Danaher from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Finally, Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $100.68.
In other news, SVP Angela S. Lalor sold 42,988 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.29, for a total value of $4,397,242.52. Following the transaction, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the completion of the transaction, the executive vice president now directly owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Over the last quarter, insiders sold 237,043 shares of company stock valued at $24,194,886. 12.20% of the stock is currently owned by company insiders.
WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/02/21/danaher-co-dhr-shares-bought-by-bailard-inc.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.